Dr. Bond practiced for twenty-two years and we will be utilizing his vast experience in clinical practice along with his experience in the nutraceutical industry which includes eighteen years as a nutritional and marketing consultant for Standard Process, where he contributed as a national speaker for that period as well. With almost 500 national lectures, he spoke on the topics of endocrinology, cardiology, hepatic dysfunction, immune disorders and more with regards to nutraceutical, whole foods and herbal therapy. In his capacity, he introduced and trained physicians in the science of nutraceuticals and herbs as alternatives to traditional pharmacologic medicine. Dr. Bond provided developmental input on many new products that afforded Standard Process immense national and international success. His landmark book, published in 2013, “Practicing with Integrity and Excellence, How to Take Your Practice from Good to Great,” sets a new standard for the incorporation of nutraceuticals into traditional medical, chiropractic, osteopathic, acupuncture, and naturopathic practices.
Dr. Bond has been working closely with Dr. Goulding in the creation of our new gummy line and our future products. “I’ve known Bruce for a number of years and feel truly blessed to have him on our team. With a truly unique background of expertise in not just nutraceuticals and herbs, but compliance of federal regulations, he brings a serious approach to moving forward. Having developed over a dozen new and exciting products for GRPS, we are anticipating robust growth.” Dr. Goulding goes on to explain, “As a traditionally trained physician at Loyola Medical School in Chicago, I became aware of a vast dearth of knowledge in most physicians. Relying on traditional pharmaceuticals for treatment, we were ignoring important breakthroughs in alternative medicine, including cannabinoids and nutraceutical combinations that in many ways are superior to traditional practice. I began to realize after much encouragement from Dr. Bond, that a preventative approach to wellness and a gentler approach to therapy is not just better but preferable on many levels. Even more important, quite possibly, was the ability to possibly deal with addiction and the toxicity of the various pharmacological compounds that are currently being used.”
Dr. Bond is excited about moving forward and states, “I see an opportunity with GRPS to utilize my background in ways that I never thought possible. With the growth of the company, we will showcase products and product combinations that are going to be widely enjoyed by customers…pharmaceutical companies maybe not so much.
Working on completing an important board of directors, GRPS will be announcing the production of our future lines soon.
About Gold River Productions Inc. (GRPS):
Gold River Productions will focus on market-targeted products including, but not limited to rare cannabinoids and effective products where a particular need is identified. Products for pain relief, sleep, etc. that will be distributed through convenience stores, independent pharmacies and more will have mass appeal to the market.
This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to a number of risks and uncertainties, many of which are outside Gold River’s control. These include but are not limited to the impact of competitors’ products, services and pricing; product demand; market acceptance; new product development; reliance on key strategic alliances; the regulatory environment; fluctuations in operating results; and other risks which are detailed from time to time in the Company’s filings with the Securities and Exchange Commission and/or OTC Markets. Gold River disclaims any obligation to update or alter its forward-looking statements whether as a result of new information, subsequent events or otherwise.
Investor caution/added risk and uncertainties for investors in companies claiming involvement in COVID-19 initiatives
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatments or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
Gold River Productions, Inc.